Clinical Trial Update: A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203) [Phase 2]

View source ↗

Summary

A Phase 2 study assessing early bactericidal activity, safety, tolerability, and PK of multiple oral doses of Telacebec (Q203) in treatment-naïve, sputum smear-…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Tuberculosis

Drugs mentioned

• Telacebec (Q203) (Telacebec)

Snippet

Sponsor: Qurient Co., Ltd. | Conditions: Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB | Phase 2 | Status: COMPLETED